Maintaining a healthy body composition is important to improve physical functioning and mobility in patients with axial spondyloarthritis receiving biologics, a new study indicated.
Bimekizumab is currently approved in the United States for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
The study unveils how tryptophan, typically a beneficial force in the body, transforms into a pathway leading to inflammatory diseases like rheumatoid arthritis.
Although it is one of the oldest medications used to treat patients with inflammatory bowel disease (IBD) and an effective treatment for an associated arthritis condition called spondyloarthritis (SpA), sulfasalazine's mechanism of action has been unclear.